Natera, Inc. (NTRA) Partners to Enroll MRD+ CRC in Phase 2a Trial

Natera (NTRA) will use its Signatera MRD test to identify patients for TransCode's Phase 2a TTX-MC138 trial in the PRE-I-SPY program. The trial aims to extend the use of MRD beyond detection. Success depends on positive Phase 2a results and evidence of improved outcomes.

Original reporting
Published Oct 13, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Natera, Inc. (NTRA) Partners to Enroll MRD+ CRC in Phase 2a Trial — source image
Decision brief

The 30-second read

$NTRABullishMed
01

Why it matters

The partnership signals potential expansion of Natera's addressable market and may prompt analysts to raise price targets.

02

Market read

First‑report of a strategic trial partnership that could enhance Natera's growth prospects.

03

What to watch

The financial terms of the partnership and any upfront payments were not disclosed.

Relevance 8/10Novelty 8/10Timing: today

Background

Natera's Signatera is a circulating tumor DNA (ctDNA) test used for minimal residual disease detection. Extending its use to interventional trials could open new revenue streams.

Company-level read

Ticker impact

$NTRABullishHigh confidence
Context

Natera announced a partnership to enroll colorectal cancer patients in TransCode's Phase 2a TTX-MC138 trial using its Signatera MRD test.

Expected impact

likely modest upside as investors price in the new trial collaboration

Evidence & confidence

First‑report partnership with a biotech trial; market typically reacts positively to expanded test applications.

Market effects

May broaden adoption of MRD testing across oncology trials, supporting the liquid biopsy sector.

Primarily U.S. biotech market; limited immediate regional effect.

Highlights growing interest in precision oncology worldwide.

Counterpoint

If the trial fails to show benefit, the partnership could become a cost without revenue upside.

Key entities

  • Natera, Inc.

    US‑listed provider of genetic testing services.

  • TransCode Therapeutics

    Developer of the TTX-MC138 colorectal cancer therapy.

Related articles

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

$NTRAMedAI 8/10

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.